当前位置: 首页 >> 检索结果
21. Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
作者: Xinyang Hu.;Jinlong Zhang.;Seokhun Yang.;Jun Jiang.;Xiaoping Peng.;Dongsheng Lu.;Yibin Pan.;Lijun Guo.;Jilin Li.;Wenming He.;Hao Zhou.;Jun Pu.;Jinyu Huang.;Fan Jiang.;Qiang Liu.;Daqing Song.;Liang Lu.;Zhenfeng Cheng.;Bin Yang.;Jianliang Ma.;Peng Chen.;Shiqiang Li.;Zhaohui Meng.;Lijiang Tang.;Yongzhen Fan.;Eun-Seok Shin.;Shengxian Tu.;Chang-Wook Nam.;William F Fearon.;Bon-Kwon Koo.;Jian'an Wang.; .
来源: Lancet. 2025年405卷10488期1491-1504页
Revascularisation decisions based on angiography-derived fractional flow reserve (FFR) or optimisation of stent implantation with intravascular ultrasound yield superior clinical outcomes compared with percutaneous coronary intervention (PCI) guided by angiography alone. However, the differences in outcomes when a single approach is used for both purposes remain unclear. We aimed to assess the non-inferiority of angiography-derived FFR versus intravascular ultrasound guidance in terms of clinical outcomes at 12 months in patients with angiographically significant stenosis.
22. Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
作者: Ajay J Kirtane.;Philippe Généreux.;Bruce Lewis.;Richard A Shlofmitz.;Suhail Dohad.;Jithendra Choudary.;Thom Dahle.;Andres M Pineda.;Kendrick Shunk.;Akiko Maehara.;Alexandra Popma.;Bjorn Redfors.;Ziad A Ali.;Mitchell Krucoff.;Ehrin Armstrong.;David E Kandzari.;William O'Neill.;Carlye Kraemer.;Krista M Stiefel.;Denise E Jones.;Jeff Chambers.;Gregg W Stone.; .
来源: Lancet. 2025年405卷10486期1240-1251页
Coronary artery calcification is common among patients undergoing percutaneous coronary intervention (PCI), and severe coronary artery lesion calcification is associated with increased procedural complexity, stent under-expansion, and high rates of intraprocedural complications and out-of-hospital adverse events. Whether calcium ablation before stent implantation can mitigate these adverse events is not currently established. We aimed to prospectively compare orbital atherectomy with a balloon angioplasty-based strategy before stent implantation for the treatment of severely calcified coronary lesions.
23. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
作者: Marc P Bonaca.;Andrei-Mircea Catarig.;Kim Houlind.;Bernhard Ludvik.;Joakim Nordanstig.;Chethana Kalmady Ramesh.;Neda Rasouli.;Harald Sourij.;Alex Videmark.;Subodh Verma.; .
来源: Lancet. 2025年405卷10489期1580-1593页
Peripheral artery disease is a highly morbid type of atherosclerotic vascular disease involving the legs and is estimated to affect over 230 million individuals globally. Few therapies improve functional capacity and health-related quality of life in people with lower limb peripheral artery disease. We aimed to evaluate whether semaglutide improves function as measured by walking ability as well as symptoms, quality of life, and outcomes in people with peripheral artery disease and type 2 diabetes.
24. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Jason S Richardson.;Deborah M Anderson.;Jason Mendy.;Lauren C Tindale.;Sufia Muhammad.;Tobi Loreth.;Sarah Royalty Tredo.;Kelly L Warfield.;Roshan Ramanathan.;Jorge T Caso.;Victoria A Jenkins.;Patrick Ajiboye.;Lisa Bedell.; .
来源: Lancet. 2025年405卷10487期1343-1352页
Chikungunya disease is a growing global public health concern. Vimkunya (previously chikungunya virus virus-like particle vaccine, previously PXVX0317) is a single-dose, pre-filled syringe for intramuscular injection. Here, we report safety, tolerability, and immunogenicity data for Vimkunya versus placebo in healthy adolescents and adults aged 12-64 years, and evaluate lot-to-lot consistency.
25. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.
作者: Antoni Castells.;Enrique Quintero.;Luis Bujanda.;Susana Castán-Cameo.;Joaquín Cubiella.;José Díaz-Tasende.;Ángel Lanas.;Akiko Ono.;Miquel Serra-Burriel.;Eladio Frías-Arrocha.;Cristina Hernández.;Rodrigo Jover.;Montserrat Andreu.;Fernando Carballo.;Juan Diego Morillas.;Dolores Salas.;Raquel Almazán.;Inmaculada Alonso-Abreu.;Jesús M Banales.;Vicent Hernández.;Isabel Portillo.;Mercedes Vanaclocha-Espí.;Mariola de la Vega.; .
来源: Lancet. 2025年405卷10486期1231-1239页
Colonoscopy and the faecal immunochemical test are accepted strategies for colorectal cancer screening in the average-risk population (ie, people aged ≥50 years without personal or family history of colorectal cancer). In this trial, we aimed to compare whether invitation to screening with faecal immunochemical test was non-inferior to colonoscopy in a screening programme.
26. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Lauren C Tindale.;Jason S Richardson.;Deborah M Anderson.;Jason Mendy.;Sufia Muhammad.;Tobi Loreth.;Sarah Royalty Tredo.;Roshan Ramanathan.;Victoria A Jenkins.;Lisa Bedell.;Patrick Ajiboye.; .
来源: Lancet. 2025年405卷10487期1353-1361页
Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death.
27. Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial.
作者: Mohamed Abdel-Fattah.;Christopher Chapple.;David Cooper.;Suzanne Breeman.;Helen Bell-Gorrod.;Preksha Kuppanda.;Karen Guerrero.;Simon Dixon.;Nikki Cotterill.;Karen Ward.;Hashim Hashim.;Ash Monga.;Karen Brown.;Marcus Drake.;Andrew Gammie.;Alyaa Mostafa.;Rebecca Bruce.;Victoria Bell.;Christine Kennedy.;Suzanne Evans.;Graeme MacLennan.;John Norrie.; .
来源: Lancet. 2025年405卷10484期1057-1068页
Overactive bladder is a common problem affecting women worldwide, with a negative effect on their social and professional lives. Before considering invasive treatments, guidelines recommend urodynamics to identify detrusor overactivity. However, the clinical-effectiveness and cost-effectiveness of urodynamics has never been robustly assessed in this cohort of women. We aimed to compare the clinical-effectiveness and cost-effectiveness of urodynamics plus comprehensive clinical assessment (CCA) versus CCA only in the management of women with refractory overactive bladder symptoms.
28. Behavioural interventions to increase uptake of FIT colorectal screening in Scotland (TEMPO): a nationwide, eight-arm, factorial, randomised controlled trial.
作者: Kathryn A Robb.;Ben Young.;Marie K Murphy.;Patrycja Duklas.;Alex McConnachie.;Gareth J Hollands.;Colin McCowan.;Sara Macdonald.;Ronan E O'Carroll.;Rory C O'Connor.;Robert J C Steele.
来源: Lancet. 2025年405卷10484期1081-1092页
Uptake of colorectal cancer screening is suboptimal. The TEMPO trial evaluated the impact of two evidence-based, theory-informed, and co-designed behavioural interventions on uptake of faecal immunochemical test (FIT) colorectal screening.
29. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
作者: Fatoumata Diallo.;Fadima C Haidara.;Milagritos D Tapia.;Clara P Dominguez Islas.;Mark R Alderson.;William P Hausdorff.;Lionel Martellet.;Nancy Hosken.;Dhananjay Kapse.;Prasad S Kulkarni.;Kelly Townsend-Payne.;Francesca Vanni.;Christine M Posavad.;Samba O Sow.;Karen L Kotloff.;Wilbur H Chen.; .
来源: Lancet. 2025年405卷10484期1069-1080页
Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT) when co-administered with routine childhood vaccines at ages 9 months and 15 months.
30. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.
作者: Vamshi Jogiraju.;Pallavi Pawar.;Jenna Yager.;John Ling.;Gong Shen.;Anna Chiu.;Emma Hughes.;Ramesh Palaparthy.;Christoph Carter.;Renu Singh.
来源: Lancet. 2025年405卷10485期1147-1154页
Long-acting antiretrovirals can address barriers to HIV pre-exposure prophylaxis (PrEP), such as stigma and adherence. In two phase 3 trials, twice-yearly subcutaneous lenacapavir was safe and highly efficacious for PrEP in diverse populations. Furthering long-acting PrEP efforts, this study assessed the pharmacokinetics and safety of two once-yearly intramuscular lenacapavir formulations.
31. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
作者: Degu Jerene.;Kristian van Kalmthout.;Jens Levy.;Jason Alacapa.;Natasha Deyanova.;Tanyaradzwa Dube.;Andrew Mganga.;Bianca Tasca.;Alexsey Bogdanov.;Egwuma Efo.;Katya Gamazina.;Anna Marie Celina Garfin.;Volodymyr Kochanov.;Adrian Leung.;Norma Madden.;Noriah Maraba.;Christopher Finn McQuaid.;Liberate Mleoh.;Baraka Onjare.;Rachel Powers.;Yana Terleiva.;Job van Rest.;Agnes Gebhard.;Katherine Fielding.;Salome Charalambous.
来源: Lancet. 2025年405卷10485期1155-1166页
The impact of digital adherence technologies on tuberculosis treatment outcomes remains poorly understood. We investigated whether smart pillboxes and medication labels can reduce poor treatment outcomes in patients with tuberculosis.
32. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
作者: Anwen Xiong.;Lei Wang.;Jianhua Chen.;Lin Wu.;Baogang Liu.;Jun Yao.;Hua Zhong.;Jie Li.;Ying Cheng.;Yulan Sun.;Hui Ge.;Jifang Yao.;Qin Shi.;Ming Zhou.;Bolin Chen.;Zhengxiang Han.;Jinliang Wang.;Qing Bu.;Yanqiu Zhao.;Junqiang Chen.;Ligong Nie.;Gaofeng Li.;Xingya Li.;Xinmin Yu.;Yinghua Ji.;Daqiang Sun.;Xiaohong Ai.;Qian Chu.;Yu Lin.;Jiqing Hao.;Dingzhi Huang.;Chengzhi Zhou.;Jinlu Shan.;Hongzhong Yang.;Xuewen Liu.;Jing Wang.;Yanhong Shang.;Xiaodong Mei.;Jie Yang.;Dongmei Lu.;Mingxiu Hu.;Zhongmin Maxwell Wang.;Baiyong Li.;Michelle Xia.;Caicun Zhou.
来源: Lancet. 2025年405卷10481期839-849页
Ivonescimab is a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor, yielding promising clinical outcomes for patients with advanced non-small cell lung cancer in early-phase studies. We compared the efficacy and safety of ivonescimab with pembrolizumab in patients with programmed cell death ligand-1 (PD-L1)-positive advanced non-small cell lung cancer.
33. Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial.
作者: Larissa I van der Windt.;Job Klumper.;Ruben G Duijnhoven.;Marjolein Kok.;Carrie Ris-Stalpers.;Marjon A de Boer.;Anton H van Kaam.;Eva Pajkrt.;Ben W Mol.;Kate F Walker.;Fionnuala M McAuliffe.;Joris A van der Post.;Carolien Roos.;Martijn A Oudijk.; .
来源: Lancet. 2025年405卷10483期1004-1013页
Tocolytics are recommended in international guidelines as treatment for threatened preterm birth. Atosiban, an oxytocin receptor antagonist, is a registered tocolytic drug specifically indicated for the treatment of threatened preterm birth. Although tocolytics have been shown to delay birth, benefits on neonatal outcomes have not been demonstrated. In the APOSTEL 8 trial we aimed to assess superiority of tocolysis with atosiban compared with placebo in threatened preterm birth from 30 weeks and 0 days (30+0 weeks) to 33+6 weeks of gestation in improving neonatal morbidity and mortality.
34. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.
作者: Philippe Gevaert.;Martin Desrosiers.;Marjolein Cornet.;Joaquim Mullol.;Eugenio De Corso.;Nesil Keles Turel.;Jorge Maspero.;Shigeharu Fujieda.;Luo Zhang.;Ana R Sousa.;Samantha J Woods.;Angela M Davis.;Stein Schalkwijk.;Dawn Edwards.;Prerna Ranganathan.;Richard Follows.;Carolynne Marshall.;Joseph K Han.; .
来源: Lancet. 2025年405卷10482期911-926页
Chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms are frequently driven by type 2 inflammation. Depemokimab is the first ultra-long-acting biological drug engineered with enhanced interleukin-5 binding affinity, high potency, and an extended half-life, enabling twice per year dosing and sustained type 2 inflammation inhibition. The ANCHOR-1 and ANCHOR-2 trials investigated the efficacy and safety of depemokimab in people with CRSwNP.
35. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.
作者: Francis Couturaud.;Jeannot Schmidt.;Olivier Sanchez.;Alice Ballerie.;Marie-Antoinette Sevestre.;Nicolas Meneveau.;Laurent Bertoletti.;Jérôme Connault.;Ygal Benhamou.;Joël Constans.;Thomas Quemeneur.;François-Xavier Lapébie.;Gilles Pernod.;Gaël Picart.;Antoine Elias.;Caroline Doutrelon.;Claire Neveux.;Lina Khider.;Pierre-Marie Roy.;Stéphane Zuily.;Nicolas Falvo.;Philippe Lacroix.;Joseph Emmerich.;Isabelle Mahé.;Julien Boileau.;Azzedine Yaici.;Sylvain Le Jeune.;Dominique Stéphan.;Pierre Plissonneau-Duquene.;Valérie Ray.;Marc Danguy des Déserts.;Rafik Belhadj-Chaidi.;Bouchra Lamia.;Yves Gruel.;Emilie Presles.;Philippe Girard.;Cécile Tromeur.;Farès Moustafa.;Vincent Rothstein.;Karine Lacut.;Solen Melac.;Sophie Barillot.;Patrick Mismetti.;Silvy Laporte.;Dominique Mottier.;Guy Meyer.;Christophe Leroyer.; .
来源: Lancet. 2025年405卷10480期725-735页
In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.
36. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
作者: Roland Veltkamp.;Eleni Korompoki.;Kirsten H Harvey.;Emily R Harvey.;Cornelia Fießler.;Uwe Malzahn.;Viktoria Rücker.;Joan Montaner.;Valeria Caso.;Igor Sibon.;Peter Ringleb.;Omid Halse.;Klemens Hügen.;Sabine Ullmann.;Carolin Schuhmann.;Gabriele Putz Todd.;Kirsten Haas.;Elena Palà.;Stéphanie Debette.;Morgane Lachaize.;Tim D'Aoust.;Christian Enzinger.;Stefan Ropele.;Simon Fandler-Höfler.;Melanie Haidegger.;Yanzhong Wang.;Hatem A Wafa.;Virginia Cancelloni.;Maria Giulia Mosconi.;Gregory Y H Lip.;Deirdre A Lane.;Walter E Haefeli.;Kathrin I Foerster.;Viktoria S Wurmbach.;Peter Brønnum Nielsen.;Karim Hajjar.;Patrick Müller.;Sven Poli.;Jan Purrucker.;Mona Laible.;Lucio D'Anna.;Yolanda Silva.;Reyes de Torres Chacon.;Patricia Martínez-Sánchez.;Marion Boulanger.;Bo Norrving.;Guillaume Paré.;Rolf Wachter.;George Ntaios.;Charles D A Wolfe.;Peter U Heuschmann.; .
来源: Lancet. 2025年405卷10482期927-936页
Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but the benefits and risks in survivors of intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage.
37. Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study.
作者: Jim Christenson.;Michael D Hill.;Richard H Swartz.;Corey Adams.;Oscar Benavente.;Leanne K Casaubon.;Sheldon Cheskes.;Aravind Ganesh.;Jonathan Dave Garman.;Cameron Harris.;Devin R Harris.;Kathy Heard.;Sandra Jenneson.;Yatika Kohli.;Michelle Leroux.;Diana Mayor-Nunez.;George Medvedev.;Manu Mehdiratta.;Laurie J Morrison.;Johanna Maria Ospel.;Sarah Pennington.;Yael Perez.;Daniel Selchen.;Alexander Stebner.;John Tallon.;Aleksander Tkach.;Pieter Richard Verbeek.;Michael Tymianski.
来源: Lancet. 2025年405卷10478期571-582页
Nerinetide is a neuroprotectant effective in preclinical models of acute ischaemic stroke when administered within 3 h of onset. However, the clinical evaluation of neuroprotectants in this short timeframe is challenging. We sought to establish the feasibility, safety, and effectiveness of nerinetide when given before hospital arrival within 3 h of symptom onset of suspected stroke.
38. Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial.
作者: Michael D Hill.;Mayank Goyal.;Andrew M Demchuk.;Bijoy K Menon.;Thalia S Field.;William C Guest.;Jorg Berrouschot.;Albrecht Bormann.;Mirko Pham.;Karl G Haeusler.;Diedrick W J Dippel.;Pieter J van Doormaal.;Franziska Dorn.;Felix J Bode.;Brian A van Adel.;Demetrios J Sahlas.;Richard H Swartz.;Leodante Da Costa.;Johanna M Ospel.;Rosalie V McDonough.;Karla J Ryckborst.;Mohammed A Almekhlafi.;Kathy J Heard.;David J Garman.;Corey Adams.;Yatika Kohli.;Bridget A Schoon.;Brian H Buck.;Mario Muto.;Atif Zafar.;Hauke Schneider.;Jonathan A Grossberg.;Leonard L L Yeo.;Jason W Tarpley.;Marios-Nikos Psychogios.;Jonathan M Coutinho.;Nicola Limbucci.;Volker Puetz.;Michael E Kelly.;Bruce C V Campbell.;Sven Poli.;Alexandre Y Poppe.;Jai J Shankar.;Ronil Chandra.;Dar Dowlatshahi.;George A Lopez.;Luigi Cirillo.;Aimen Moussaddy.;Michael Devlin.;Pablo Garcia-Bermejo.;Jennifer L Mandzia.;Mona Skjelland.;Anne Hege Aamodt.;Frank L Silver.;Timothy J Kleinig.;Guglielmo Pero.;Jens Minnerup.;Ryan A McTaggart.;Ajit S Puri.;Albert H Y Chiu.;Gernot Reimann.;Gordon J Gubitz.;Marie-Christine Camden.;Seon Kyu Lee.;Eric Sauvageau.;Sibu Mundiyanapurath.;Donald F Frei.;Hana Choe.;Marcello Rocha.;Jan Gralla.;Peter Bailey.;Sebastian Fischer.;Thomas Liebig.;Konstantin Dimitriadis.;Dheeraj Gandhi.;René Chapot.;Albert Jin.;Ameer E Hassan.;Wim van Zwam.;Ilko L Maier.;Martin Wiesmann.;Wolf-Dirk Niesen.;Rajiv Advani.;Agnethe Eltoft.;Negar Asdaghi.;Cynthia Murphy.;Luca Remonda.;Darshan Ghia.;Olav Jansen.;Markus Holtmannspoetter.;Victoria Hellstern.;Karsten Witt.;Annette Fromme.;Shahid M Nimjee.;David Turkel-Parella.;Dominik Michalski.;Christian Maegerlein.;Carol Huilian Tham.;Michael Tymianski.; .
来源: Lancet. 2025年405卷10478期560-570页
In the ESCAPE-NA1 trial, treatment with nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, was associated with improved functional outcome among patients with acute ischaemic stroke due to large vessel occlusion undergoing endovascular thrombectomy without co-treatment with an intravenous thrombolytic agent. There was no benefit when intravenous thrombolytic agent co-treatment was used. We sought to confirm the clinical benefit of nerinetide in the absence of previous intravenous thrombolytic drug treatment.
39. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial.
作者: Weili Li.;Jing Lan.;Ming Wei.;Lan Liu.;Chengbei Hou.;Zhifeng Qi.;Chuanhui Li.;Liqun Jiao.;Qi Yang.;Wenhuo Chen.;Shuling Liu.;Xincan Yue.;Qinglin Dong.;Haicheng Yuan.;Zongen Gao.;Xiangbin Wu.;Changming Wen.;Tong Li.;Changchun Jiang.;Di Li.;Zuoquan Chen.;Junfeng Shi.;Wanchao Shi.;Jinglin Yuan.;Yijie Qin.;Binglong Li.;Marc Fisher.;Wuwei Feng.;Ke Jian Liu.;Xunming Ji.; .
来源: Lancet. 2025年405卷10477期486-497页
Endovascular treatment improves the recanalisation rate for patients with acute ischaemic stroke; however, even with endovascular treatment, approximately half of patients do not have a favourable functional outcome. We aimed to evaluate the effect of normobaric hyperoxia combined with endovascular treatment on functional outcomes up to 90 days after treatment in patients who had an acute ischaemic stroke with large-vessel occlusion.
40. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
作者: Nirosen Vijiaratnam.;Christine Girges.;Grace Auld.;Rachel McComish.;Alexa King.;Simon S Skene.;Steve Hibbert.;Alan Wong.;Sabina Melander.;Rachel Gibson.;Helen Matthews.;John Dickson.;Camille Carroll.;Abigail Patrick.;Jemma Inches.;Monty Silverdale.;Bethan Blackledge.;Jessica Whiston.;Michele Hu.;Jessica Welch.;Gordon Duncan.;Katie Power.;Sarah Gallen.;Jacqueline Kerr.;K Ray Chaudhuri.;Lucia Batzu.;Silvia Rota.;Edwin Jabbari.;Huw Morris.;Patricia Limousin.;Nigel Greig.;Yazhou Li.;Vincenzo Libri.;Sonia Gandhi.;Dilan Athauda.;Kashfia Chowdhury.;Tom Foltynie.
来源: Lancet. 2025年405卷10479期627-636页
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.
|